An Introduction to Market Access and Economic Evaluations

Date : 28/01/2016
Time: 09:30h - 14:30h
Location: Parc Científic de Barcelona (PCB) – Sala 4 - Torre I, C. Baldiri Reixac, 4, 08028 Barcelona
City : Barcelona
Inscription :


When speaking about the Spanish healthcare environment, the complex process of introducing a new drug to the Spanish market is becoming of great importance. Therefore, it is necessary that those who are involved in the development and introduction of new drugs are knowledgeable about:

  • How to access the Spanish market; the different levels of decision-making and who are the regulatory bodies that influence the approval and introduction of a new medicine.
  • The new negotiation techniques for the innovative price and reimbursement agreements that can accelerate Spanish market access.
  • How to use health economic tools in the introduction of new medicines in the Spanish market.

ASEBIO and Insights in life Sciences (ilS) co-organize this training course in order to provide practical advice and detailed information about the complex Spanish market access process for new drugs.  This course aims to share the latest innovative agreements in drug pricing and reimbursement, as well as the health economics tools that can be valuable during the introduction and launch of medicines into the Spanish market.    




The training course is going to be delivered by Spanish top-notch representatives, professionals, and teachers from the areas of Market Access and Health Economics:

Dr. Pepi Hurtado, Partner in ilS

Dr. Pepi Hurtado has extensive experience in the pharmaceutical and biotechnology industry at global and national levels. She worked as senior consultant at IMS Health and as an independent consultant at her own company (DelScience). Prior to becoming a consultant, she had experience as a researcher both in academia and pharmaceutical industry. Additionally. Dr. Hurtado has a broad training in scientific fields, holds an MSc in Pharmacy (University of Barcelona) and a Ph.D. in Pharmaceutical Technology (University of London).

Dr. Itziar Escudero, Partner in ilS

Dr. Itziar Escudero has extensive experience in entrepreneurship, business development and strategic consulting in the pharmaceutical, biotech and medical device industries, both at national and international level. She worked for international firms such as Ernst & Young and PwC. Dr. Escudero holds an M.B.A. degree from the University of California, a Ph.D. in Biochemistry and Molecular Biology from the University of Barcelona, and a Masters in Chemical Sciences with a specialization in Biochemistry from Universidad Autónoma de Madrid.

Dr. Laura Pellisé, Senior Research Fellow at the Centre for Research in Health and Economics (CRES)

Dr. Laura Pellisé is Senior Researcher at the Centre for Research in Economics and health (CRES) at the Department of Economics and Business at Universitat Pompeu Fabra (UPF). She has a degree in Economics from Universitat de Barcelona, holds an MSc in Health Policy and Management from Harvard University and a Ph.D. in Economics from UPF.

Dr. Pellisé has been a visiting professor at the Department of Economics of Universidad Carlos III of Madrid. She also joined the Spanish Ministry of Health as a technical advisor in 1997. She held, since 2001, top management positions in the largest private hospital group in Spain, USP (now Grupo Quirón Salud), and then was managing director of the Vall d’Hebron Institute of Oncology (VHIO).

She joined the CRES at UPF in 2011, as its Director. She is member of the group of experts appointed by the European Commission for the evaluation of SME (Small Medium Enterprises) in health care. She co-directs the Master in Health Policy and Management of UPF.

Dr. Carme Pinyol, Pricing and Reimbursement and Market Access Senior Expert

Dr. Pinyol is graduated from Universitat Autònoma de Barcelona (UAB) with a degree in Medicine and Surgery and a Postgraduate in Medicine for the Pharmaceutical Industry, a Postgraduate degree in Statistical Techniques for the Life Sciences and a Postgraduate degree in clinical trial design for the life sciences. She holds a Master degree in Health Economics and Pharmacoeconomics from Universitat Pompeu Fabra (UPF), a Master degree in Social Healthcare from University of Castilla-La Mancha, an Executive Programme at ESADE, and currently she is completing her Ph.D. in Health Economics.

Dr. Pinyol, Founder and Director of INNOVA - Strategic consulting, worked for 23 years in different areas of the pharmaceutical industry (sales, training, marketing, discount medical economics, health, price and market access) and held various management positions. She was the Director of Pricing and Health Economics for two years in a multinational consultancy.

Dr Antoni Gilabert-Perramon, the Managing Director of Pharmacy and Medicines in the Catalan Health Service (Government of Catalonia).

Dr. Gilabert has an extensive trajectory in the health department based on planning and developing pharmaceutical and drug policies. He has a degree in Pharmacy from Universitat de Barcelona, holds an MSc in Health Policy and Healthcare Management and a Ph.D. in pharmacology from Universitat de Barcelona. Additionally, he collaborates in teaching and training activities organized by different international universities, schools, and health institutions. 

Dr. Gilabert is currently responsible for the planning, management, control, and evaluation of the pharmaceutical, orthopedics and supplementary benefits in Catalonia. 




09:45 – 10:00

Welcome the attendees
ASEBIO and ilS

10:00 – 10:45

Introduction to Market Access and Health Economics
Itziar Escudero, Partner at ilS

10:45 – 11:30

Organization of the Spanish National Health System
Dr. Pepi Hurtado, Partner at ilS

11:30 – 12:00

Coffee Break

12:00 – 13:00

Budget Impact models  
Dr. Carme Pinyol, Founder and director of INNOVA-strategic consulting

13:00 – 14:00

Types of Economic Evaluations  as Market Access tools
Dr. Laura Pellisé, Senior researcher at the Centre de Recerca en Economia de la Salut of Pompeu Fabra University

14:00 – 14:30

Closing Speech; Innovative Price Agreements 
Dr. Antoni Gilabert, Managing Director of Pharmacy and Medicines at the Catalan Health Service.

Download Program